Rejected from Current Biology? The 7 Best Journals to Submit Next

Choose the next journal by the asset the rejection did not invalidate. That creates a cleaner decision than stepping down a prestige ladder.

Write the asset in one sentence, then test every candidate journal against it. If a destination requires a different central asset, that is a new paper strategy, not a simple transfer.

Current Biology sits at the broad-biology, general-interest end of the Cell Press family (impact factor 7.7, 2026 JCR release). The right next venue depends on whether your rejection was about reach (the paper is broad but did not read that way) or about scope (the paper is excellent but specialist). The shortlist below spans both routes.

The two routes are different decisions. The cross-disciplinary route (Nature Communications, PLOS Biology, eLife) bets that the science is broad and the Current Biology rejection was about framing. The Cell Press cascade route (Cell Reports, iScience) accepts that the paper is excellent but field-bounded and routes it to a venue that does not require general-interest reach. Proceedings B and BMC Biology are the organismal-biology and open-access fallbacks respectively.

Current Biology may offer an author-controlled Cell Press transfer after a decision. Read the live offer carefully: confirm its deadline, the receiving journal, and which files or reviews will move. A transfer is useful only when the manuscript genuinely fits the receiving journal, and it does not promise a particular decision or speed.

The realistic ladder looks like this. Current Biology (Tier 1, broad biology + general interest) steps down to Cell Reports (still broad and cross-disciplinary, but without the general-interest bar), then to iScience (the open-access cascade target for technically rigorous broad-biology work). For organism-level or ecology and evolution work, Proceedings B is a strong lateral move outside Cell Press.

The most common Cell Press cascade across the portfolio runs Cell, then Molecular Cell or a discipline-specific title, then Cell Reports, then iScience, and a Current Biology rejection slots naturally into the back half of that ladder.

If that transfer is rejected too, or if no transfer was offered, the next tier is a broad-interest journal outside the portfolio: Nature Communications or PLOS Biology if the breadth claim is real, eLife if you want the work judged in the open. Do not treat the cascade as automatic ladder-descent.

If the rejection said the science is field-bounded rather than under-framed, a respected field journal that reaches your actual readers is often a better strategic move than a broad-biology retry, even at a lower headline metric. The best next journal is the one where your existing manuscript is easiest to evaluate fairly.

The following testable patterns map to manuscript-level repairs. They are diagnostics grounded in Current Biology's public general-interest remit, not measured shares of private editorial decisions.

Current Biology's editorial identity is general interest across biology. The triage filter asks two questions: is the work correct and important, and will a biologist in a different subfield care? You can test that second question before resubmitting.

General-interest framing exists only in the cover letter. If the cover letter claims broad relevance but the abstract, introduction, and figures read like a specialist paper, the manuscript package contradicts itself. The manuscript must carry the audience case.

Check whether the abstract opens with subfield jargon and whether Figure 1 assumes the reader already cares about the system. Fix the mismatch by making the broad biological question and evidence legible before the specialist mechanism.

Current Biology's author guidance caps the abstract at 175 words and the main text of a Report at 5,000 words, so the broad framing has to do its work inside a tight space. The breadth claim has to live in the manuscript, not the letter.

Story completeness is short of Current Biology's bar. Current Biology wants a complete story, not a promising fragment, because a general-interest reader will not follow a half-finished argument. We repeatedly see Current Biology submissions where a phenotype is shown without its mechanism, or a mechanism is proposed without the rescue or epistasis experiment that would close the causal chain.

Reviewers and editors read these as incomplete rather than wrong, and at a general-interest journal incomplete is a rejection. Before resubmitting, ask whether a non-specialist could follow the claim from observation to conclusion without an act of faith. If a key control or comparison is missing, add it before you move, because the same gap will surface at the next journal too.

Subfield significance presented as general significance. A strong result in behavioral ecology, sensory neuroscience, or developmental biology may still belong to a specialist audience. If the discussion explains the advance entirely in specialist terms and adds a broad implication as an afterthought, route the paper honestly or strengthen the evidenced cross-field consequence.

This is the cleanest signal that the paper belongs in Cell Reports, a field-specific journal, or Proceedings B rather than back in the Current Biology queue.

Statistical support thin for the breadth of the claims. The analysis and sample-size rationale should match the breadth of the conclusion. Inspect whether the statistical test matches the data structure and whether uncertainty is visible; do not use an arbitrary replicate count as a universal rule.

A general-interest claim invites scrutiny from readers across biology, so the statistical foundation has to be stronger, not weaker, than a specialist paper would need. Tighten the analysis and the reported effect sizes before you resubmit anywhere.

Do not send the same file down a journal ladder. Classify whether the decision concerned reach, scope, evidence, or presentation, then make the corresponding repair before selecting the next owner.

If reviewers or your own read flagged a missing control, comparison, or causal link, that is real evidence work, not a formatting pass. If the decision was purely about general-interest fit and the science is complete, reframe the abstract and introduction for the new audience before resubmitting.

Use the current appeal route only when you can document a material factual or process error. If a Cell Press transfer is offered, confirm its terms in the decision letter and receiving-journal workflow rather than assuming every file or review will move.

This guidance uses the official Cell Press, ScienceDirect, PLOS, eLife, Springer Nature, and Royal Society author pages cited below. The routing framework is Manusights editorial judgment. Confirm live fees, deadlines, transfer terms, and article requirements before submitting.

• How to choose a journal for your paper
• Current Biology journal guide: fit, scope, review
• What pre-submission peer review includes

The earlier routing table maps rejection signals to venue types. Before retargeting, identify the manuscript asset that should not be diluted just to resemble the next journal.

Retargeting should change emphasis, not the underlying record. Do not add new claims to compensate for rejection. This follow-up addresses manuscript preservation after routing and is distinct from the August 17 rejection-signal map; the repeated treatment makes short-window attribution indeterminate.

Official sources accessed 2026-08-18.

Official and authoritative sources accessed 2026-08-17.

1. Current Biology aims and scope, Cell Press.

1. Moving house: an introduction to the Cell Press transfer system, Cell Press CrossTalk.

1. Article transfer, Cell Press.

1. iScience journal home, Cell Press.

1. Proceedings B for authors, The Royal Society.